-
Mashup Score: 0Increasing tissue requirements in lymphoma trials may exclude patients with high risk disease or worse prognosis - 2 year(s) ago
Key Points. Patients who receive core needle biopsy are more likely to have poor risk disease features and inadequate tissue for molecular analyses.Increasing t
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 14Burkitt’s Lymphoma | NEJM - 2 year(s) ago
Review Article from The New England Journal of Medicine — Burkitt’s Lymphoma
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma - 2 year(s) ago
Key Points. A new TMTV/ECOG-PS prognostic score was validated in 2174 DLBCL patients of all ages treated in clinical trials and real-world series.The combined T
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma - 2 year(s) ago
Key Points. Our study contextualizes the single-arm ELARA trial by providing historical control data from clinically similar patients on usual care.Tisagenlecle
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Key Points. Race, ethnicity, and body-mass index did not impact CAR T-cell efficacy or neurotoxicity outcomesHispanic patients were more likely to experience se
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
Khoan Vu, Matthew Joshua Frank; CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse, Blood Advances, , bloodadvances.2022008031, htt
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals - 2 year(s) ago
Key Points. Continuous exposure to a CD19xCD3 bispecific molecule induces T-cell exhaustionTreatment-free intervals transcriptionally reprogram and functionally
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial - 2 year(s) ago
In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bi…
Source: Taylor & FrancisCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Mantle-Cell Lymphoma | NEJM - 2 year(s) ago
Review Article from The New England Journal of Medicine — Mantle-Cell Lymphoma
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet
Pts who had core 💉bx for #DLBCL more likely to have advanced stage, IPI>=3 and inadequate tissue for molecular analyses compared to 🔪bx 5-yr EFS and OS worse among pts who had 💉bx vs. 🔪bx Huge implications for the design of #DLBCL trials #lymsm https://t.co/frQE4EROHQ